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ARTICLE
A mechanistic modelling approach for the determination of the mechanisms of
inhibition by cyclosporine on the uptake and metabolism of atorvastatin in rat
hepatocytes using a high throughput uptake method
Simon J. Cartera , Alex S. Ferecskob , Lloyd Kingb , Karelle Menochetb , Ted Partonc and Michael J.
Chappella
aBiomedical and Biological Systems Laboratory, School of Engineering, University of Warwick, Coventry, United Kingdom; bUCB Pharma Ltd,
Slough, United Kingdom; cMekinopsis Ltd, London, United Kingdom
ABSTRACT
1. Determine the inhibition mechanism through which cyclosporine inhibits the uptake and metab-
olism of atorvastatin in fresh rat hepatocytes using mechanistic models applied to data generated
using a high throughput oil spin method.
2. Atorvastatin was incubated in fresh rat hepatocytes (0.05–150nmol/ml) with or without 20min
pre-incubation with 10nmol/ml cyclosporine and sampled over 0.25–60min using a high
throughput oil spin method. Micro-rate constant and macro-rate constant mechanistic models
were ranked based on goodness of fit values.
3. The best fitting model to the data was a micro-rate constant mechanistic model including
non-competitive inhibition of uptake and competitive inhibition of metabolism by cyclosporine
(Model 2). The association rate constant for atorvastatin was 150-fold greater than the dissociation
rate constant and 10-fold greater than the translocation into the cell. The association and dissoci-
ation rate constants for cyclosporine were 7-fold smaller and 10-fold greater, respectively, than
atorvastatin. The simulated atorvastatin-transporter-cyclosporine complex derived using the
micro-rate constant parameter estimates increased in line with the incubation concentration of
atorvastatin.
4. The increased amount of data generated with the high throughput oil spin method, combined
with a micro-rate constant mechanistic model helps to explain the inhibition of uptake by cyclo-
sporine following pre-incubation.
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Introduction
Movement from the blood into the liver is a key component
of the elimination of drugs from the body. From there they
may be metabolised, excreted into the bile or excreted back
into the blood (Shitara et al., 2006). If the majority of the
clearance from the blood into the liver is via a transporter
protein, and this is much greater than the relevant metabolic
and/or biliary clearance, then this is a rate limiting step in
the elimination of the drug from the body (Kimoto et al.,
2015; Patilea-Vrana & Unadkat, 2016). For example for car-
boxylic acids (e.g. atorvastatin), uptake of drugs into the liver
via a saturable carrier protein such as organic anion trans-
porting polypeptide (OATP) may be the rate limiting step in
clearance from the blood (Shitara, 2011).
Atorvastatin is an HMG-CoA reductase inhibitor used to
treat hypercholesterolaemia, and is the third most prescribed
drug in the USA (Fuentes et al., 2018). Atorvastatin is taken
up into hepatocytes with; 96%–98% of the uptake as carrier
mediated in rat hepatocytes, high intracellular binding (frac-
tion unbound ¼ 0.011–0.015; Kulkarni et al., 2016; Paine
et al., 2008; Yabe et al., 2011), and metabolism through
rCyp3a into ortho or para substituted hydroxylated metabo-
lites (Lau et al., 2006; Watanabe et al., 2010).
Cyclosporine (CsA) is an effective immunosupressant for
use in organ transplantation, but its use is now limited due
to cholestasis and nephrotoxicity (Fricker & Fahr, 1997) and
has largely been replaced by immunosuppressants with less
severe side effects, such as tacrolimus (Amundsen et al.,
2012; Skalicka et al., 2009). CsA inhibits the uptake of both
endogenous acids such as taurocholic acid (Fricker & Fahr,
1997) and xenobiotics such as atorvastatin (Amundsen et al.,
2010) and pitavastatin (Shitara & Sugiyama, 2017) in a com-
petitive (Amundsen et al., 2010) or non-competitive manner
(Shitara & Sugiyama, 2017), depending on whether the
inhibitor is co-incubated or pre-incubated respectively.
Disposition of CsA in rat hepatocytes has been shown to be
CONTACT Michael J. Chappell M.J.Chappell@warwick.ac.uk Biomedical and Biological Systems Laboratory, School of Engineering, University of Warwick,
Coventry CV4 7AL, United Kingdom
Supplemental data for this article can be accessed here.
 2019 Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
XENOBIOTICA
https://doi.org/10.1080/00498254.2019.1652781
passive with no contribution from transporters and reaches a
steady state within 5min with 86% of the initial dose
bound to membrane and intracellular constituents. Any free
drug is then metabolised slowly by rCyp3a (Prueksaritanont
et al., 1992; Umehara & Camenisch, 2012). The membrane
binding of CsA after 5min was found to be associated with
an 85 KDa protein (Ziegler & Frimmer, 1986), which is the
same as rOatp (Hagenbuch & Gui, 2008).
Statins are often dosed concomitantly with immunosup-
pressants in the clinic to treat the associated hypercholester-
olaemia that occurs after organ transplantation, making the
assessment of inhibition of statin disposition highly import-
ant (Imamura et al., 2005; Skalicka et al., 2009). The inhibition
seen in vitro with atorvastatin and CsA, was also observed
clinically in healthy volunteers with a 15-fold higher plasma
exposure of atorvastatin and its metabolites compared to
those on tacrolimus, with an increased risk of rhabdomyoly-
sis in chronic patients (Lemahieu et al., 2005).
In order to investigate the uptake of substrates in sus-
pended hepatocytes, some means of separating the cells
from the media following incubation is required. Soars et al.
(2007) and Harrison et al. (2018) rapidly centrifuged samples,
and then analysed the loss from the media assuming no or
little loss of material from the cells. A more complex method
is to spin the media containing hepatocytes in an individual
microtube through a layer of oil into a dense bottom layer
in which the cells are lysed and then analyse the pellet. The
use of the oil spin method, was initially limited to radiola-
belled substrates (Schwarz et al., 1975) with possible confu-
sion from metabolites, until the more readily accessible
analysis by liquid chromatography–mass spectrometry (LC-
MS) was developed (Baker & Parton, 2007; Lu et al., 2006).
The advantage of individual microtubes is that suitable cen-
trifuges with a rapid acceleration and deceleration are avail-
able, and this determines when the earliest timepoint for
measurement can be taken. Li et al. (2013) described a high
throughput oil spin method in an 8-well format, with the
first timepoint at 30 s, which was the first paper to show a
method using more than a single microtube to increase the
throughput of the oil spin method. To further increase the
throughput of the assay, the method used in Li et al. (2013)
needs to be miniaturised to make use of a centrifuge with
an acceleration and deceleration similar to those used with
individual microtubes.
It is increasingly common to use compartmental mechan-
istic models to simultaneously describe the data obtained
from hepatocytes across a range of concentrations and time-
points (Baker & Parton, 2007; Grandjean et al., 2014a;
Menochet et al., 2012b; Shitara & Sugiyama, 2017). Unlike
the two-step method published by Ishigami et al. (1995),
mechanistic models do not assume linearity over initial time-
points (Li et al., 2013), and can be used to describe the kinet-
ics of substrate and quantifiable metabolites as well as
differences in passive rates travelling to and from the cell
(Grandjean et al., 2014a; Menochet et al., 2012b), to enable
better predictions of human pharmacokinetics for transporter
substrates (Jones et al., 2012). The use of mechanistic models
derived using the Michaelis-Menten kinetics equation
(termed macro-rate constant models in this article) are based
on assumptions originally designed for use in enzymology and
applied to transporters: It is assumed that the association to
the transporter is very rapid in comparison to the dissociation
from the transporter and that the amount of substrate at the
transporter is much larger than the total amount of transport-
ers and thus the substrate is at equilibrium in a very short
space of time (Grandjean et al., 2014a; Segel, 1993b). It then
follows that the rate of translocation into the cell is the rate
limiting step in the movement of substrate into the cell
(Grandjean et al., 2014a; Segel, 1993b). However, these
assumptions are not formally tested, but can be done so
through the use of micro-rate constant mechanistic models.
The aim of this paper is to determine the mechanism of
inhibition of CsA on the uptake and metabolism of atorvastatin
in fresh rat hepatocytes. This will be met through the following
objectives: develop a novel high throughput oil-spin method
optimised for use with fresh rat hepatocytes that allows mul-
tiple concentrations to be assessed simultaneously; the amount
of information obtained will then be used to develop and
compare micro-rate constant and Michaelis-Menten (macro-
rate constant) mechanistic models to simultaneously describe
the initial uptake kinetics and metabolism of atorvastatin, and
the complex inhibition exhibited by cyclosporine; the
Michaelis-Menten assumptions described above can be for-
mally tested; the mechanistic models will be guided by a struc-
tural identifiability analysis to aid in parameter estimation.
Methods
Chemicals
Atorvastatin sodium was obtained from Sequoia Research
Products Ltd (Pangbourne, UK). Cyclosporine, Percoll, high
temperature silicone oil (175633), Krebs-Henseleit buffer
powder (KHB, 1L), sodium chloride, HEPES, collagenase
(C5138) and Trypan blue (0.4%) were obtained from Sigma-
Aldrich (Poole, UK). Dimethyl sulfoxide (DMSO), methanol
and water were obtained from Thermo Fisher Scientific Inc.
(Loughborough, UK) and were of analytical grade.
Animals
Male Lewis rats (350–480 g) were obtained from Charles
River (Margate, UK). They were housed three to a cage lined
with sawdust, forage mix and shredded paper in rooms
maintained at a temperature of 20 ± 2 C with a relative
humidity of 45%–55% on a 12 h light:dark cycle with access
to food and water ad libitum. All procedures performed were
approved by the local UCB ethical review committee accord-
ing to the Home Office animal procedures act (1986) by
licenced individuals. Data were generated from cells isolated
from three rats on different occasions.
Isolation of hepatocytes
Hepatocytes were isolated using a two stage liver perfusion
with collagenase (Seglen, 1976), with the exception that
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collagenase was perfused at only 20–24ml/min and not
50ml/min to prevent undue pressure increases in the liver.
Under terminal general anaesthesia with isoflurane, the liver
was perfused with a calcium free-buffer (500ml Liver
Perfusion Medium, Invitrogen, Paisley, UK) at a rate of 25ml/
min in a humid 38 C temperature controlled cabinet. The
medium was then changed to modified KHB (118mM NaCl,
5mM KCl, 1.1mM MgSO4, 2.5mM CaCl2, 1.2mM KH2PO4,
25mM NaHCO3, 10mM glucose supplemented with 12.5mM
HEPES [pH 7.4]) and saturated with O2/CO2, containing colla-
genase (0.012%–0.013% w/v). Both the liver perfusion
medium and modified KHB containing collagenase were kept
at 38 C in jacketed beakers and stirred and gassed continu-
ously with 95% O2/5% CO2 for at least 20min prior to use.
The liver was then dissected free and transferred to ice cold
modified KHB, the cells were released by the use of a cell
scraper (Thermo Fisher Scientific Inc.) and filtered through
70mm filters into 50ml falcons (BD, Oxford, UK). The cells
were centrifuged at 50 g for 5min at 4 C and the super-
natant removed. The pellets were re-suspended in a 30:70
mixture of Percoll: modified KHB and spun at 70 g for 5min
at 7 C. This step led to cells of high viability (>98%) as
determined by the trypan blue (0.4%) exclusion test with
greater than 250 106 cells/liver. The cells were kept on ice
throughout isolation and used within 3 h of isolation.
Incubations
Custom-made 16-channel Teflon blocks (two columns of
eight round-ended and bottomed troughs from Radleys,
Saffron Walden, UK, see Figure 1) were pre-incubated with
2ml of 2 106 cells/ml for 20min, at 38.9 C (temperature
inside the Teflon blocks was 37 C) and 109 strokes/min,
placed lengthwise in an oscillating water bath (Julabo,
Peterborough, UK); using this technique, cells were gently
agitated to keep them in suspension, while the large inter-
face between medium and air helped achieve adequate oxy-
gen exchange. Kolhatkar & Polli (2010) simulated competitive
and non-competitive experiments to determine what analysis
method best returned the correct inhibition type. It was con-
cluded that use of a single inhibitor concentration at or
above the KI and numerous substrate concentrations were
sufficient to correctly identify the type of inhibition
(Kolhatkar & Polli, 2010) and was therefore initiated experi-
mentally. CsA (2mmol/l) was dissolved in DMSO and added
during pre-incubation where required (or DMSO alone in
controls), with a final concentration of 10 nmol/ml. Omnistrip
(0.32ml) PCR eight-tube strips (Thermo Fisher Scientific) were
layered with 50 ml 3M NaCl and 100ml high temperature sili-
cone oil and placed in a six-position PCR strip rotor in an
Eppendorf 5417R centrifuge (Eppendorf, Cambridge, UK).
High temperature silicone oil was chosen as its density
does not change significantly between room temperature
and 37 C (1.047 ± 0.006 and 1.043 ± 0.004 g/ml respectively,
values are mean± SD, n¼ 3) whilst still remaining more
dense than modified KHB at 37 C (1.024 ± 0.013 g/ml, values
are mean± SD, n¼ 3). The difference in density at 37 C and
shape of the menisci before centrifugation (Figure 1(a)) is
critical to ensure that the aqueous layers do not mix due to
‘flipping’, and this was the driving factor in miniaturising the
assay. The high throughput method was initially validated
against that obtained using the single tube method for UCB-
X and was found to be similar to that obtained by Baker &
Parton (2007) (data not shown).
Following a pre-incubation of 20min, 10 ml of atorvastatin
solution (0.05, 0.25, 0.5, 2.5, 5, 25, 50 and 150 nmol/ml final
concentration) in DMSO was spiked into the Teflon blocks
using an 8-way multichannel pipette. 8 100ml samples,
containing an assumed 2 105 cells (the minimum number
of cells required to spin through the oil layer) were taken
from the Teflon blocks (Figure 1, step 1) at pre-defined time-
points (0.25, 0.58, 0.92, 1.25, 2.5, 5, 10, 20, 30, 40, 50 and
60min), gently pipetted down the side of the Omnistrips
and immediately centrifuged for 5 s up to 7000 rpm
(Figure 1, steps 2 and 3). This was sufficient for the cells to
pellet into the bottom of the 3M sodium chloride (bottom
layer), and enabled the generation of a large number of sam-
ples within a short space of time (up to 384 samples in
80min). The Omnistrips were then transferred to a 96 well
matrix latch rack on ice for sample extraction (Thermo
Fisher Scientific).
Carryover
To check for carryover, 150 nmol/ml of atorvastatin was incu-
bated in modified KHB in the absence of cells at 37 C in a
Teflon block. 100 ml of media was taken and treated as per
samples with hepatocytes. Carryover of atorvastatin was neg-
ligible (<0.1%, data not shown).
Sample extraction
Within 2 h of finishing the experiment, the top media layer
and most of the middle oil layer were aspirated carefully to
prevent the flipping of layers, and leaving sufficient volume
of the oil to cover the bottom layer (Figure 1, step 4). The
remaining bottom and middle layer were refrigerated over-
night to enable easier disruption of cells. Due to the centrifu-
gation step, the menisci present before centrifugation were
vastly decreased, making sample extraction more straightfor-
ward (see Figure 1, steps 2 and 3). Ice cold methanol (60ml,
containing 600 pmol/ml dextromethorphan as an internal
standard) was added to each tube and mixed using a multi-
channel pipette on ice until the pellet was disrupted
(Figure 1, step 5). The matrix racks containing the Omnistrips
were centrifuged at 4000 g at 5 C for 5min (Figure 1, step
6), 50 ml of the supernatant was pipetted into a Phenomenex
2ml deep well plate (Macclesfield, UK) and 250 ml of 40:60
methanol:water was added (Figure 1, steps 6 and 7).
Standard curves for atorvastatin were prepared as follows: 5,
1, 0.5, 0.1, 0.05, 0.01 and 0.005mmol/l stocks were prepared
in DMSO and then diluted by 1 in 100 in methanol giving
final concentrations of 50, 10, 5, 1, 0.5, 0.1 and 0.05 nmol/ml,
respectively. A 50 ml aliquot of this solution was then
extracted as per the samples. To examine loss from the
media, 50 ml of the top layer from the latter two studies was
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carefully removed from the four lowest concentrations across
a range of timepoints (0.25, 0.58, 0.92, 1.25, 2.5, 5, 10, 20, 30,
40, 50 and 60min) prior to aspiration of the top and middle
layer, and frozen.
HPLC-MS analysis
Reconstituted samples were analysed by high-performance
liquid chromatography (HPLC)–high resolution mass spec-
trometry (HRMS) operated in positive ion mode using an
Accela HPLC system and a Q-Exactive Orbitrap mass spec-
trometer (Thermo Scientific, Hemel Hempstead, UK). For
HPLC analysis, a Luna C18 100Å 50 2mm, 5 mm column
(Phenomenex, Cheshire, UK) was used with a flow rate of
0.6ml/min at 40 C. Mobile phase A was composed of H2O
containing 0.1% formic acid, and mobile phase B was com-
posed of acetonitrile containing 0.1% formic acid. The gradi-
ent system used was as follows: initially, 20% of mobile
phase B was held for 0.1min followed by a linear gradient to
95% of mobile phase B from 0.1 to 0.8min, 0.5min at 95%
of mobile phase B, a third linear gradient to 20% of mobile
phase B at 1.3–1.31min, and finally, a 0.49min re-equilibra-
tion period at 20% of mobile phase B. Injections of 10 ml
were made by a CTC Prep and Load (PAL) autosampler (CTC
Analytics, Zwingen, Switzerland). For MS analysis, the capil-
lary temperature was set at 380 C, the source potential was
3100 V, and the source heater was set at 350 C. Data were
acquired in centroid mode at a resolution setting of 35000
(full width half maximum). The mass spectrometer was oper-
ated in a selected positive ion scanning mode, monitoring
for the protonated mass of atorvastatin (MH559.26028) with
an isolation window of 4Da. The internal standard (dextro-
methorphan) was monitored at MH272.20151. The HPLC-MS
data were acquired in a single run, processed and analysed
using LCQuan software (version 2.7. Thermo Fisher Scientific
Inc.). Atorvastatin demonstrated good linearity up to
50 nmol/ml with R2> 0.99 and a limit of quantitation of
0.05 nmol/ml.
Data analysis
Assuming that 2 105 cells were centrifuged into the 50 ml
of 3M NaCl, and that extraction of atorvastatin from the pel-
let into the methanol was complete, the bottom layer con-
centration was converted to cellular concentration using a
cellular volume of per 1 106 cells (Baker & Parton, 2007;
Reinoso et al., 2001; Yoshikado et al., 2017):
cell½  ðnmol=mlÞ ¼ bottom layer½ ðVb þ VcellÞ
Vcell
(1)
where Vb is the volume of the bottom layer of 3M NaCl
(0.05ml) and Vcell is the cell volume for 2 105 cells. As
Figure 1. Flow chart of high throughput assay starting from incubation and separation of hepatocytes from the media via an oil spin method (steps 1–4) to extrac-
tion and analysis via LC-MS (steps 5–9). Numbers in squares relate to the step number in time order as described in the Methods section. LC-MS: liquid chromatog-
raphy–mass spectrometry.
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multiple volumes have been reported for the cellular volume
from 0.0022 to 0.0065ml per 1 106 cells (Baker & Parton,
2007; Reinoso et al., 2001; Yoshikado et al., 2017), initial
micro-rate constant mechanistic models for atorvastatin only
(see Figure 2(a) without inhibition) were evaluated in
Monolix 2018R2 (Lixoft, Antony, France) with the inverse of
the different volumes used as the observation in the model
(see Table 1, Equation (11)). The Vcell estimate which best
described the data was determined using the weighted
Bayesian information criterion (wBIC; Burnham & Anderson,
2002):
wBIC ¼ e
0:5DiPn
i e
0:5Di (2)
and
Di ¼ BICi  BICmin (3)
where n is the total number of different models evaluated
(in this case, three different volume models), e0:5Di is the
relative likelihood of the difference between the individual
BIC (BICi) and the lowest BIC and
Pn
i e
0:5Di is the sum of
relative likelihoods from the mechanistic models. A volume
0.0011ml/2 105 cells, obtained using an initial estimate of
0.0013ml/2 105 cells (Baker & Parton, 2007), with a
wBIC 1 and was thus the most likely cell volume given the
data. The volumes of 0.00078ml/2 105 cells (Yoshikado
et al., 2017) and 0.0004ml/2 105 cells (Reinoso et al., 2001)
each had a wBIC 0, and were therefore not used further.
The reciprocal of Vcell from 0.0011ml/2 105 cells ¼ 906/ml
used in the model observations (see Supplementary Material)
was then fixed in the rest of the parameter estimations from
the mechanistic models. Due to the large level of extraction
of atorvastatin from the media into the cell, atorvastatin
could only be detected in the media in four out of 24 sam-
ples in the incubations at 0.05 nmol/ml, and only up to 5min
at 2.5 nmol/ml. The data from medium loss were therefore
not used in any further analysis due to their sparsity (data
not shown). Qualitative metabolite identification for atorvas-
tatin was conducted, but only semi-quantitative profiles were
generated, metabolite standards were not available.
Therefore whilst the semi-quantitative metabolite information
is useful, it was not included in the mechanistic models, and
can be found in the Supplementary Material.
Mechanistic models
The development of a nonlinear mathematical micro-rate
constant model, with the use of two rate constants to
describe passive movement of substrate between the
medium and cells (kfA and kbA respectively), and the move-
ment of substrates via a transporter compartment has been
published for pitavastatin, defined as micro-rate constant
models here (Grandjean et al., 2014a). Whilst a single passive
rate constant, with transporter mediated uptake through
Michaelis-Menten kinetics, with the inclusion of fraction
unbound in the cell and medium and Michaelis-Menten
metabolism was described by Menochet et al. (2012a).
Michaelis-Menten uptake models are defined as macro-rate
constant models here.
In the present study, both micro-rate constant mechanis-
tic models (Figure 2(a,b), Models 1 and 2, see Supplementary
Material for ODEs) and macro-rate constant mechanistic
models (Figure 2(c,d), Models 3 and 4, see Supplementary
Material for ODEs) were evaluated for the uptake and metab-
olism of atorvastatin and the inhibition by CsA with the two
passive rate constants given above, and the inclusion of
metabolic clearance through the Michaelis-Menten equation.
Two separate passive rate constants (kfA and kbA) were used,
as the use of a single passive rate constant with a fraction
unbound in the cell led to large deviations of the predicted
concentrations from the observed concentrations for the
macro-rate constant models (see Supplementary Material).
The amount of free transporters available for the uptake
of atorvastatin (Tf) are not normally known, but the total
amount of transporters (To) is assumed to be constant, then
Tf can be eliminated via the conservation law derivation for
transporters (Grandjean et al., 2014b) to give:
Tf ¼ To  S2  I2  I3 (4)
where S2 and I2 are the amount of atorvastatin and CsA
bound to transporter respectively and I3 is the atorvastatin-
transporter-CsA complex involved in non-competi-
tive inhibition.
Structural identifiability of the mechanistic models
Prior to parameter estimation, it is important to determine,
whether all of the parameters or combinations of parameters
are identifiable and that the model is at least structurally
locally identifiable (Bearup et al., 2013; Grandjean et al.,
2014b). If any parameters are unidentifiable, then they can be
effectively assigned any value during parameter estimation,
without affecting the observations, making conclusions
regarding the unidentifiable parameters and model responses
difficult (Evans et al., 2002). All the mechanistic models were
evaluated for structural identifiability given known inputs and
output observations (see Supplementary Material) using the
Identifiability Analysis package in Mathematica 11.3
(Anguelova et al., 2012; Karlsson et al., 2012).
Parameter estimation
The incubation concentrations of atorvastatin and CsA were
converted to amounts (nmol) by multiplying by the sampled
medium volume that holds 2 105 cells (V1¼ 0.1ml). The
final chosen model was based on the wBIC (Equation (2)) to
more harshly penalise over-parameterisation within the mod-
els compared to the Akaike information criterion (Aho et al.,
2014; Burnham & Anderson, 2002), as well as the sum of the
individual and population predictions of the relative mean
square root error (RMSRE) given by:
% RMSRE ¼ 100
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
m
X ObservediPredictedi
Observedi
 2s
(5)
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where m is the total number of datapoints, and the sum of
all individuals (i) and datapoints in the model.
Initial parameter estimates were obtained for atorvastatin
only micro-rate constants using starting values of 1 for the
transporter mediated parameters (kaA, kdA, ktA and To) and
the passive rate constant out of the cell (kbA), as no literature
information was available regarding the determination of
these estimates within Monolix 2018R2 (Lixoft, Antony,
France), whilst for the macro-rate constant parameters
(Vmax.up, Km.up, Vmax.met and Km.met), initial atorvastatin param-
eter estimates were obtained through the use of a Yamazaki
plot (Yamazaki et al., 1993) and a double-reciprocal
(Lineweaver-Burke plot) for uptake and a double-reciprocal
plot for metabolism (see Supplementary Material). For the
simultaneous determination of parameter estimates for ator-
vastatin in the presence of CsA, all parameters were assumed
to follow a log-normal distribution with a proportional
residual error model in Monolix 2018R2. Only the parameter
estimates for the best fitting model will be discussed (Figure
2(b), Model 2), whilst the other models are included in the
Supplementary Material for comparison purposes. To evalu-
ate whether the parameter estimates for Model 2 were sensi-
tive to the initial starting point, an assessment was
undertaken in Monolix 2018R2 whereby the initial starting
point was taken as a random number based on the final par-
ameter estimates. This was conducted five times and the
(a)
(b)
(c)
(d)
Figure 2. Schematic of the micro-rate constant models (Models 1 and 2) consisting of medium, transporter and intracellular compartments, and macro-rate con-
stant models (Models 3 and 4) consisting of medium and intracellular compartments. Atorvastatin following pre-incubation with CsA with competitive (a and c)
and non-competitive (b and c) inhibition of uptake respectively were modelled. CsA: cyclosporine.
Table 1. Structural identifiability of the micro-rate constant models and macro-rate constant models, and goodness of fit values obtained during parameter esti-
mation (Models 1–4).
Model
Inhibition
type
No. of unknown
parameters
No. of
states
Identifiability
result
No. of parameters
to be identifiable (d.o.f.) BIC (wBIC) % RMSRE (indþ pop)
1 C 11 5 SI 0 5514.2 (0.45) 21þ 61¼ 82
2 NC 12 6 SI 0 5513.8 (0.54) 211 495 69
3 C 8 3 U 2: Km.up, KI.up, Km.met, KI.met 5608.0 (0) 29þ 94¼ 123
4 NC 8 3 U 2: Vmax.up, Kinact.up, Km.met, KI.met 5524.8 (0) 29þ 96¼ 125
Best fitting model outlined in bold.
BIC: Bayesian information criterion; C: competitive; d.o.f.: degrees of freedom; NC: non-competitive; RMSRE: relative mean square root error; SI: structurally
(locally) identifiable; U: unidentifiable; wBIC: weighted BIC.
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estimates obtained showing the lowest 2.LL are reported
here, whilst the other parameter estimates obtained from
the assessment are included in the Supplementary Material.
Comparison of parameter estimates to literature
To allow comparison between the parameter estimates
obtained from the micro-rate constant models to known lit-
erature values, the equation used to describe saturable
uptake is re-arranged to yield the classic Michaelis-Menten
form for the parameter estimates obtained. This is based on
the assumption that binding to the uptake transporter active
site is extremely rapid and therefore considered to be at a
pseudo steady state (Grandjean et al., 2014a), and that the
amount of drug at the uptake transporter binding site is
greater than the total amount of uptake transporter binding
sites (Segel, 1993b) to give the maximum uptake velocity
(Vmax.up):
Vmax:up ðpmol=min=1106cellsÞ ¼ ktATo  1000 (6)
where ktA is the atorvastatin translocation rate constant into
the cell, To is the total amount of transporters involved in
the uptake of atorvastatin (see Supplementary Material) and
1000 is the scalar translation from nmol/min/1 106 cells to
pmol/min/1 106 cells. To enable the concentration at which
50% of uptake transporter binding sites are occupied (Km.up),
calculated in nmol/ml, the transporter association rate con-
stant for atorvastatin (kaA) must first be converted into ml/
nmol/min/1 106 cells by multiplying by 0.5055ml, the
medium volume in which 1 106 cells are present:
Km:up ðnmol=mlÞ ¼ kdA þ ktAð Þ5 V1kaA (7)
where kdA is the dissociation rate constant from the trans-
porter for atorvastatin and V1¼ 0.5055ml. To enable the
inhibition dissociation constant (KI.up) to be calculated in
nmol/ml, the transporter association rate constant for CsA
(kaC) must be converted into ml/nmol/min/1 106 cells by
multiplying by 0.5055ml as per Km.up, and then calculated
according to:
KI:up ðnmol=mlÞ ¼ kdC5 V1kaC (8)
where kdC is the transporter dissociation rate constant from
the transporter for CsA. Km.met and KI.met were converted to
concentration (nmol/ml) by dividing by Vcell (0.0011ml) and
then multiplied up to per 1 106 cells:
Km:met or KI:met nmol=mlð Þ ¼ nmol5 Vcell : (9)
For comparison of non-competitive inhibition of uptake,
KI.up needs to be multiplied by the dimensionless a term,
which is used to determine the effect that CsA binding to
the transporter has on the subsequent atorvastatin binding
to transporter (Copeland, 2013):
Kinact ðlMÞ ¼ KI:upa: (10)
Transporter uptake clearance (CLup) and metabolic clear-
ance (CLmet) were calculated by dividing Vmax by Km for the
relevant clearance:
CLup or CLmet ðll=min=1106Þ ¼ VmaxKm : (11)
For the passive component, conversion to a passive diffu-
sion clearance into the cell (Pdif) or out of the cell (Pdef) were
obtained by multiplication of the passive rate constants (kfA
and kbA respectively) by the medium volume into which
1 106 cells were present (i.e. kfA500 ml), or the volume of
1 106 cells (i.e. kbA5.5 ml).
The figures in this paper were all generated in Inkscape
version 0.93, or RStudio version 1.1.463 (RStudio Inc.) running
R version 3.5.2 using cowplot with its dependencies (Wilke,
2016) and extrafont (Chang, 2014).
Results
High throughput method
The method described here took multiple concentrations
simultaneously over a timecourse using eight-way
Omnistrips, with an early sample possible at 15 s.
Timecourses over 0.25–60min for incubations of atorvastatin
from 0.05 to 150 nmol/ml, in the absence or presence of CsA
were obtained for all three experiments (see Figure 3), with
no samples lost over the three experiments due to mixing of
the oil and media layers. A total of 192 samples were
obtained relatively simply using the high throughput method
over a time period of 68min, enabling substrate and sub-
strate with inhibitor samples to be obtained from the same
set of hepatocytes within the 3 h window for the use of fresh
hepatocyte suspensions. The analysis of data from the three
experiments in a single HPLC-MS run was undertaken to
decrease inter-run variability, with a mean relative standard
deviation across all datapoints of 25% and 33% for atorvasta-
tin in the absence and presence of cyclosporine respectively.
Structural identifiability of the mechanistic models
The use of micro-rate constants to describe the uptake of
atorvastatin in the presence of CsA, combined with competi-
tive inhibition of the Michaelis-Menten metabolism (Figure
2(a,b), Models 1 and 2 for competitive and non-competitive
inhibition of uptake, respectively) and measurement of cellu-
lar atorvastatin were at least structurally locally identifiable,
with no parameters required to be known a priori (see
Table 1). For the macro-rate constant models (Figure 2(c,d),
Models 3 and 4 for competitive and non-competitive inhib-
ition of uptake respectively) with two Michaelis-Menten non-
linearities and measurement of cellular atorvastatin, the
models were structurally unidentifiable unless two of the fol-
lowing parameters were known: Vmax.up, Kinact.up, KI.met, Km.up,
KI.up and KI.met (see Table 1) for Model 3 and 4 respectively.
The structural unidentifiability for the macro-rate constant
models was manifested in the parameter estimates associ-
ated with the metabolism of atorvastatin, with unrealistic
estimates for the two unidentifiable parameters in Models 3
and 4 (Km.met¼ 340 [251–407] and 436 [296–544] nmol/ml,
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respectively, KI.met¼ 1.1 [1–1.3] and 0.32 [0.27–0.36] nmol/ml
respectively, see Supplementary Material).
Mechanistic modelling and parameter estimates
The best fitting model based on the % RMSRE and wBIC was
Model 2 (micro-rate constant model, including non-competi-
tive inhibition of atorvastatin uptake by CsA, and competitive
inhibition of atorvastatin metabolism by CsA (see Table 1,
and Supplementary Material for ODEs). Both Models 1 and 2
were almost equal in terms of BIC values (5514.2 and 5513.8,
respectively, Table 1), with a wBIC and total % RMSRE that
made Model 2 more favourable over Model 1 (wBIC ¼ 0.54
and 0.45, respectively, % RMSRE ¼ 69 and 82, respectively,
Table 1). The macro-rate constant models (Models 3 and 4,
Figure 2(c,d)) were unsupported as the best fitting models
(wBIC 0, Table 1), which coincides with the structural iden-
tifiability analysis results above.
Model 2 visually fitted the atorvastatin data in the
absence and presence of CsA relatively well (Figure 3, blue
and red, respectively), with a rapid increase up to a max-
imum at the same time as the data, which was more pro-
longed in the presence of CsA. CsA strongly inhibited the
metabolism of atorvastatin within rat hepatocytes, as can be
seen in the flat line in the individual predictions (see
Figure 3). The population fits for each model had two to four
times the % RMSRE compared to the individual fits (49%–96%
and 21%–29%, respectively, see Table 1), and therefore the
individual parameter estimates are included and discussed for
Model 2 only. A plot of the individual weighted residuals
(IWRES) against time for all the data were normally distributed
with a LOESS close to 0 (Figure 4, solid line).
The passive rate into the cell for atorvastatin (kfA) was
nine times smaller than the passive rate out of the cell for
atorvastatin (kbA), with large ranges on both parameters (1.1
[0.2–23.3] and 9.3 [0.6–36.5]/min/1 106 cells, respectively,
Table 2). The atorvastatin transporter association rate con-
stant (kaA ¼ 2.6 [1.2–13.3]/nmol/min/1 106 cells, Table 2)
was 10-fold greater than the translocation constant (ktA ¼
0.3 [0.2–0.3]/min/1 106 cells, Table 2) and 150-fold greater
than the atorvastatin transporter dissociation (kdA, 0.017
[0.015–0.021]/min/1 106 cells, Table 2). It follows then that
very quickly kaA approaches To (see Figure 5, dotted blue
line), and once atorvastatin is bound it is likely to be translo-
cated into the cell. The CsA transporter association rate con-
stant (kaC ¼ 0.36 [0.33–0.37]/nmol/min/1 106 cells, Table 2),
was seven times smaller than kaA, whilst the CsA transporter
dissociation rate constant (kdC ¼ 0.16 [0.13–0.2]/min/1 106
cells) was 10 times greater than kdA.
The Michaelis-Menten assumptions discussed previously
(Grandjean et al., 2014a; Segel, 1993a) hold here for atorvas-
tatin. This partially explains why the BIC values obtained for
Models 2 and 4 are close between the micro-rate and
macro-rate constant models (Di for the BIC ¼ 11, Table 1).
To illustrate how the different aspects of non-competitive
inhibition affect atorvastatin and CsA, parameter estimates
from Model 2 associated with the transporter (ka, kd, kt, To
and a, see Table 2 and Supplementary Material) were used
to simulate the transporter response following pre-incuba-
tion with CsA (Figure 5) using the deSolve package in R
Figure 3. Plots of atorvastatin cellular concentration against time following the addition of atorvastatin (0.05, 0.25, 0.5, 2.5, 5, 25, 50 and 150 nmol/ml) in the
absence (circles) and presence (triangles) of 10 nmol/ml of CsA. Each time course represents one experiment from one Teflon block trough. Shapes are data from
the three separate experiments, the solid line and dashed line is the average individual prediction from Model 2 in the absence and presence of 10 nmol/ml of
CsA, bounded by the max and min individual predictions (shading). CsA: cyclosporine.
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(Soetaert et al., 2010). In the absence of CsA (Figure 5, dot-
ted blue lines), as the incubation concentration of atorvasta-
tin was increased, so the kdA had a larger effect, seen as a
broadening of the peak. After pre-incubation with CsA, the
higher affinity atorvastatin competes with CsA, leading to a
decrease in atorvastatin bound (blue solid line), and also a
perturbation in the amount of CsA bound (red dotted-
dashed line). This recovers to near the initial amount of CsA
at lower atorvastatin incubation concentrations, as atorvasta-
tin is transported into the cell. The formation of the atorvas-
tatin-transporter-CsA complex initially starts at zero and
increases over time, as the incubation of atorvastatin
increases, so the complex increases (Figure 5, red
dashed line).
Discussion
To compare the passive rate constants to the values found
in the literature for atorvastatin, the passive rate constants
(kfA and kbA) were scaled from Model 2 to clearances (Pdif
and Pdef) respectively by multiplying by the relevant volume.
Pdif was 11-fold greater than Pdef (0.55 [0.1–11.7] and 0.051
[0.03–0.2] ml/min/1 106 cells respectively), possibly due to
intracellular binding of atorvastatin (Kulkarni et al., 2016;
Paine et al., 2008; Yabe et al., 2011). Pdif for atorvastatin was
minor (<1%) compared to the transporter mediated uptake
clearance (CLup ¼ 3375 [2722–10750] ml/min/1 106 cells,
Equation (11)), therefore even though the range of values on
kfA and thus Pdif estimation were large it is of little conse-
quence in the uptake of atorvastatin. The percentage of pas-
sive clearance to the overall uptake clearance is similar to
the literature contribution of passive movement to the
uptake of atorvastatin in rat hepatocyte suspensions of 1.5 %
(Yabe et al., 2011), but less than the estimated value in
plated rat hepatocytes of a 10 % passive contribution (Liao
et al., 2018).
The scaled Vmax.up value obtained from Model 2 (850
[680–1340] pmol/min/1 106 cells, Equation (6)) was similar
to that obtained from the initial estimate from a Yamazaki
plot (1253 pmol/min/1 106 cells, see Supplementary
Material), and compared favourably to that obtained from rat
hepatocytes (1340± 320 pmol/min/1 106 cells, Yabe et al.,
2011). The scaled Km.up (0.2 [0.04–0.41] nmol/ml, Equation
(7)) was similar to that seen in plated hepatocytes (0.3 nmol/
ml, although the Vmax.up was low at 58 pmol/min/mg, Liao
et al., 2018), but less than rat hepatocyte suspensions
(4 ± 4 nmol/ml, Yabe et al., 2011). Cellular volume estimates
have a large effect on both the cellular concentration calcu-
lation prior to parameter estimation, and within the models
themselves with normalised data. Yabe et al. (2011) used the
value of 0.0039ml/1 106 cells (Reinoso et al., 2001), which
gave a higher BIC value for the data presented here, and is
therefore a major contribution to the source of the
differences.
The difference in ka and kd between atorvastatin and CsA
explains the co-incubation inhibition conclusions in the
Figure 4. Plot of individual weighted residuals (IWRES) against time for Model 2 obtained using Monolix 2018R2. Points are IWRES, dashed lines are 95% confi-
dence intervals and solid line is the locally estimated scatterplot smoothing of the IWRES.
Table 2. Micro-rate constant model parameter estimates for the non-competi-
tive inhibition of atorvastatin by CsA in rat hepatocytes (Model 2).
Parameter Individual mode (min–max)
Passive
kfA (/min) 1.1 (0.2–23.3)
kbA (/min) 9.3 (0.6–36.5)
Transporter
kaA (/nmol/min) 2.6 (1.2–13.3)
kaC (/nmol/min) 0.36 (0.33–0.37)
kdA (/min) 0.017 (0.015–0.021)
kdC (/min) 0.16 (0.13–0.2)
To (nmol) 2.7 (2–3.6)
ktA (/min) 0.3 (0.2–0.3)
a 0.013 (0.007–0.023)
Metabolism
Vmax.met (pmol/min) 393 (285–500)
Km.met (nmol/ml) 18 (8–31)
KI.met (nmol/ml) 11 (6–29)
Data are the individual mode of the conditional distribution obtained from
Monolix 2018R2, n¼ 3. All parameter estimates are scaled to per 1 106 cells.
Vmax was scaled to pmol/min and Km, KI and Kinact were scaled to nmol/ml.
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literature with the KI.up ¼ 0.9 (0.8–1) nmol/ml value deter-
mined here (Equation (8)), that was similar to the IC50 value
in HEK293-OATP1B1 cells of 0.48 ± 0.34 nmol/ml (Amundsen
et al., 2010), and 0.3 nmol/ml for cis-inhibition with estradiol-
17b-glucuronide (Shitara & Sugiyama, 2017). The inhibition
on pre-incubation therefore derives from the a value of
0.013 (0.007–0.023), which, using Equation (10), gives a
Kinact.up value of 0.012 (0.0057–0.023) nmol/ml, and was the
same as that for pre-incubation with atorvastatin in
HEKOATP1B1 cells (0.021 ± 0.004 nmol/ml, Amundsen et al.,
2010), as well as the trans-inhibition value of 0.026 nmol/ml
calculated using estradiol-17b-glucuronide as a substrate
(Shitara & Sugiyama, 2017).
The Vmax.met and Km.met values obtained from Model 2
(393 [285–500] pmol/min/1 106 cells and 18 [8–31] nmol/
ml) combined to give a metabolic clearance (CLmet¼22
[16–35] ml/min/1 106 cells, Equation (11)) that was higher
than the value in the literature (4.3 ± 0.65 ml/min/1 106 cells
Sprague-Dawley rat hepatocytes, Paine et al., 2008), and
7.6 ± 0.4ml/min/1 106 cells (adjusted from rat liver micro-
somes, Watanabe et al., 2010). Km.met and KI.met were similar
(18 [8–31] and 11 [6–29] nmol/ml respectively, Table 2), on
the assumption that for CsA, the concentration inside the
cell is approximately equal to the concentration outside the
cell. This was supported by the literature, where it was
reported that 86% of the initial concentration of CsA was
measured in the cell after 5min, whilst only 16% of the initial
CsA was lost over 4 h (Prueksaritanont et al., 1992).
In conclusion, the data presented here show that the high
throughput oil spin method developed enabled multiple
concentrations to be taken simultaneously for timepoints
over a 68min experiment (192 samples). The data obtained
are adequate for the assessment of atorvastatin uptake in rat
hepatocytes and its inhibition by CsA given the models fits
and parameter estimates. Through the use of mechanistic
modelling and comparison of the % RMSRE and wBIC, a
micro-rate constant model for the non-competitive inhibition
of atorvastatin uptake by CsA and competitive inhibition of
metabolism in rat hepatocytes was supported as the best fit-
ting model to the data (Model 2). The improvement in model
fit with micro-rate constant models over the frequently used
macro-rate constant models is concurrent with those of
Grandjean et al. (2014a) with pitavastatin in hepatocytes;
with improved goodness of fit values with micro-rate con-
stant mechanistic models over macro-rate constant mechan-
istic models, and helps to further the knowledge between
substrate and inhibitor binding at a transporter level and
within the cell. The ability to return the parameter estimates
from a mechanistic model, linked to the structural identifi-
ability analysis results, highlights how the two are closely
related and should become routine moving forwards. The
quantification of CsA simultaneously with atorvastatin, as
well as quantification of metabolites with reference stand-
ards, should be considered in future work to potentially
improve the robustness of parameter estimation. Inclusion of
CsA quantification would also lead to the macro-rate con-
stant model becoming at least structurally (locally) identifi-
able. It should also be noted that the assay is currently
limited to rat hepatocytes, but the technique should be
applicable to cryopreserved human hepatocytes with modifi-
cations to the oil layer and bottom layer, and adaptation of
the slosh plates used. The availability of fresh rat hepato-
cytes, the use of the high throughput method, and low cost
in comparison to cryopreserved human hepatocytes makes
Figure 5. Model 2 plots of the simulated amounts of atorvastatin bound to the transporter against time in the absence (dotted line) and presence (solid line) of
cyclosporine (CsA). The dotted-dashed line is the amount of CsA bound to the transporter following pre-incubation, and the dashed line is the
atorvastatin–transporter–CsA complex.
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transporter mediated drug–drug interaction potential in rat
hepatocytes a good starting point which gave similar pre-
incubation non-competitive inhibition estimates in human
cell-lines with different substrates (Amundsen et al. 2010;
Shitara & Sugiyama, 2017). Optimisation of the assay for cry-
opreserved human would therefore improve the modelling
and prediction of transporter mediated drug–drug interac-
tions in the clinic.
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